NeuroBo Pharmaceuticals announced that it has submitted an Investigational New Drug application to the U.S. FDA. The IND application supports a Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist, in development for the treatment of nonalcoholic steatohepatitis.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NRBO: